Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.30 |
| ▸ | CTSB | P07858 | 2/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSH | P09668 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867665 | 0.95 | CTSK (0.38) | CTSKCTSLCTSBSLC1A3SLC1A2 | |
| SCHEMBL6245315 | 0.95 | CTSK (0.38) | CTSKCTSLCTSBSLC1A3SLC1A2 | |
| SCHEMBL9102349 | 0.94 | ANPEP (0.33) | CTSKCTSS | |
| SCHEMBL15332671 | 0.87 | — | — | |
| SCHEMBL14975129 | 0.74 | MEN1 (0.31) | — | |
| SCHEMBL1642682 | 0.74 | MEN1 (0.31) | — | |
| SCHEMBL1864711 | 0.73 | CTSK (0.36) | CTSKCTSLCTSBATMCTSS | |
| SCHEMBL4127198 | 0.73 | RNPEP (0.33) | — | |
| SCHEMBL10656233 | 0.73 | CTSK (0.34) | CTSKCTSLCTSBCTSSCTSH | |
| SCHEMBL1862554 | 0.72 | CTSK (0.39) | CTSKCTSLCTSBATMCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSK 8/4885CTSL 13/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.